# PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

> **NCT02917005** · PHASE2 · UNKNOWN · sponsor: **Hamdy A. Azim** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Exemestane
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT02917005
- **Lead sponsor:** Hamdy A. Azim
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-07
- **Primary completion:** 2021-12
- **Final completion:** 2023-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917005, "PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02917005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*